Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to “Sell”

Kura Oncology (NASDAQ:KURA) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

Several other brokerages have also commented on KURA. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. UBS Group began coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 target price on the stock. Finally, Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the company from $26.00 to $19.00 in a research note on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $28.83.

Kura Oncology Trading Down 0.5 %

NASDAQ:KURA opened at $15.96 on Wednesday. Kura Oncology has a 52 week low of $9.06 and a 52 week high of $24.17. The firm’s fifty day moving average is $18.36 and its 200-day moving average is $19.85. The firm has a market cap of $1.24 billion, a P/E ratio of -6.76 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently bought and sold shares of KURA. nVerses Capital LLC purchased a new position in shares of Kura Oncology in the third quarter valued at about $25,000. SG Americas Securities LLC bought a new stake in Kura Oncology in the first quarter valued at $110,000. Point72 DIFC Ltd purchased a new position in Kura Oncology during the 3rd quarter valued at $146,000. Quarry LP bought a new position in Kura Oncology in the 2nd quarter worth $196,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology in the 3rd quarter worth about $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.